3-(1,1-二甲基乙基)-1-(6-甲基-3-吡啶)-1H-吡唑-5-胺 | 285984-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(1,1-二甲基乙基)-1-(6-甲基-3-吡啶)-1H-吡唑-5-胺
• 英文名称: 3-(tert-butyl)-1-(6-methylpyridin-3-yl)-1H-pyrazol-5-amine
• 英文别名: 5-amino-3-tert-butyl-1-(2-methylpyridine-5-yl)pyrazole；5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-amine
• CAS: 285984-51-2
• 化学式: C₁₃H₁₈N₄
• 分子量: 230.313
• InChiKey: XCKVJAWYMIZRMF-UHFFFAOYSA-N

物化性质

• 沸点：
  379.9±42.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(1,1-二甲基乙基)-1-(6-甲基-3-吡啶)-1H-吡唑-5-胺 在 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 13.5h， 生成 1-{2-[(1H-indazol-5-yl)oxy]benzyl}-3-[3-tert-butyl-1-(6-methylpyridin-3-yl)-1H-pyrazol-5-yl]urea
  参考文献：
  名称：

  新型色烯二芳基脲类化合物,其制备方法及其用途

  摘要：

  本发明涉及通式I化合物，或其异构体、可药用盐及溶剂化物；本发明还涉及包含通式I化合物或其异构体、可药用盐及溶剂化物，以及药学上可接受的载体、赋形剂或稀释剂的组合物；本发明还涉及通式I化合物，或其异构体、可药用盐及溶剂化物，用于克服炎症、炎症相关疾病、肿瘤及窒息性气体或刺激性气体造成的急性肺损伤疾病或症状的用途；特别是用于与P38 MAPK通路有关的疾病或症状中的用途。

  公开号：

  CN106518848A
• 作为产物：
  描述：

  3-氨基-6-甲基吡啶 在 盐酸 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 22.5h， 生成 3-(1,1-二甲基乙基)-1-(6-甲基-3-吡啶)-1H-吡唑-5-胺
  参考文献：
  名称：

  Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)

  摘要：

  We report on the structure-activity relationships (SAR) of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796), an inhibitor of p38alpha MAP kinase which has advanced into human clinical trials for the treatment of autoimmune diseases. Thermal denaturation was used to establish molecular binding affinities for this class of p38alpha inhibitors. The tert-butyl group remains a critical binding element by occupying a lipophilic domain in the kinase which is exposed upon rearrangement of the activation loop. An aromatic ring attached to N-2 of the pyrazole nucleus provides important pi-CH2 interactions with the kinase. The role of groups attached through an ethoxy group to the 4-position of the naphthalene and directed into the ATP-binding domain is elucidated. Pharmacophores with good hydrogen bonding potential, such as morpholine, pyridine, and imidazole, shift the melting temperature of p38alpha by 16-17 degreesC translating into K-d values of 50-100 pM. Finally, we describe several compounds that potently inhibit TNF-alpha production when dosed orally in mice.

  DOI：

  10.1021/jm030121k

文献信息

• [EN] POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES<br/>[FR] DÉRIVÉS D'URÉE POLYAROMATIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES MUSCULAIRES
  申请人：ANAGENESIS BIOTECHNOLOGIES S A S

  公开号：WO2021013712A1

  公开（公告）日：2021-01-28

  The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

  当前的发明提供尿素衍生物，特别是具有核心结构杂环基-NH-CO-NH-芳基-O-杂环基的化合物，用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或症状，如杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症、虚弱或肌肉萎缩症。
• 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030232865A1

  公开（公告）日：2003-12-18

  Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I): 1 wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  披露了公式(I)的1,4-二取代苯并尿素化合物：1其中，公式(I)中的Ar、X、A、L和Q在本文中定义。这些化合物抑制参与炎症过程的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理状况，如慢性炎症疾病。还披露了制备这些化合物的方法以及包含这些化合物的药物组合物。
• Methods of treating cytokine mediated diseases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030130309A1

  公开（公告）日：2003-07-10

  Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar 1 ,Ar 2 ,L,Q and X are described herein. 1

  披露了使用公式(I)中描述的新芳香杂环化合物治疗特定细胞因子介导的疾病或症状的方法，其中Ar1，Ar2，L，Q和X如下所述。
• Aromatic heterocyclic compounds as antiinflammatory agents
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US06525046B1

  公开（公告）日：2003-02-25

  Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

  揭示了一种新颖的芳香杂环化合物，其化学式为(I)，其中Ar1、Ar2、L、Q和X如本文所述。这些化合物在制备用于治疗涉及炎症的疾病或病理状况，如慢性炎症性疾病的药物组合物中具有用途。还公开了制备这种化合物的方法。
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
  申请人：CHIESI FARMA SPA

  公开号：WO2013083604A1

  公开（公告）日：2013-06-13

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof: formula (I) wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

  式（I）的化合物或其药学上可接受的盐：式（I）其中R2、W、A、Y和R1如规范中定义，是p38 MAPK抑制剂，可用作抗炎药物，治疗呼吸道疾病等疾病。